PharmaFocus Today – Page 66 – media

Flu Shot Season is At Hand

By Carole Tanzer Miller HealthDay ReporterSATURDAY, Aug. 23, 2025 (HealthDay News) — With a longtime vaccine critic leading the nation’s health departments, you might be wondering whether there’s a new flu shot this fall. There is — and Health and Human Services Secretary Robert F. Kennedy Jr. says most Americans should get it. He’s basing that recommendation on the advice of a board he appointed to advise the federal government on vaccines. The U.S. Centers for Disease Control and Prevention (CDC) says people 6 months old and up should get a flu shot. That’s pretty much the same advice the CDC has given in the past. This year’s version of the flu vaccine should be widely available soon, according to KFF Health News. No shortages are anticipated. So when should you roll up your sleeve? The best time to take the jab is September, October or early November, doctors say. ...
- Source: drugdu
- 162
- August 25, 2025
Betta Pharmaceuticals discloses clinical research progress on ensartinib for postoperative adjuvant indications

Betta PharmaceuticalsOn the morning of August 25th, the company announced that in April 2022, the National Medical Products Administration (NMPA) approved the clinical trial of Ensartinib Hydrochloride Capsules (Bemena®, hereinafter referred to as “Ensartinib”) for the adjuvant treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) after surgery. Recently, an interim analysis of the clinical trial, as assessed by the Independent Data Monitoring Committee (IDMC), demonstrated positive results, meeting the study’s pre-specified primary endpoint and demonstrating statistically significant and clinically important benefits. Detailed data from this study will be presented at a major international academic conference this year. The company’s team is actively preparing application materials and aiming to submit the NDA for this new indication as soon as possible. https://finance.eastmoney.com/a/202508253492884316.html
- Source: drugdu
- 150
- August 25, 2025
How NMN Helps Longevity Enzymes Fight Aging

Sirtuin enzymes are a family of NAD+-dependent deacetylase proteins, also known as sirtuins, which mediate many of the beneficial effects of NMN on the brain and intestines of aged mice. Left: Sirtuin 1 bound to the sirtuin activator resveratrol (magenta). Right: Sirtuin 6 bound to the sirtuin activator (yellow) and NAD+ (red). Sirtuins act like molecular switches, orchestrating the countless processes necessary for cellular health and longevity. These specialized proteins function as NAD+-dependent deacetylases—enzymes that remove acetyl groups from other proteins, effectively altering their function. They regulate processes ranging from DNA repair and energy metabolism to inflammation and cellular stress responses. However, sirtuin activity naturally declines with aging. Sirtuins are particularly intriguing because of their dependence on NAD+ (nicotinamide adenine dinucleotide). This crucial coenzyme serves as the “fuel” for sirtuin activity. Unfortunately, NAD+ levels naturally decline with age, dropping by up to 50% in mammals during the transition from youth ...
- Source: drugdu
- 156
- August 25, 2025
Obtained U.S. FDA Drug Registration Approval for Nicardipine Hydrochloride Injection

SecuritiesDaily News Network reported on the evening of August 21 that Jianyou SharesThe company recently received an approval letter from the U.S. Food and Drug Administration (FDA) for nicardipine hydrochloride injection, 25mg/10mL (2.5mg/mL), according to an announcement. https://finance.eastmoney.com/a/202508213490940546.html
- Source: drugdu
- 116
- August 25, 2025
The world’s first hexavalent rotavirus vaccine is approved for marketing

Recently, Sinopharm Group China National Biotec Group Wuhan Biological ProductsThe Institute’s oral hexavalent, reassortant, live attenuated rotavirus vaccine (Vero cell-based) (trade name: Wushengerlunbao®) has been officially approved for marketing by the National Medical Products Administration. This product, the world’s first and most expensive rotavirus vaccine, is a Class 1 new biological drug for preventive use in China and is primarily used to prevent acute gastroenteritis in infants and young children caused by rotavirus https://finance.eastmoney.com/a/202508223492196812.html
- Source: drugdu
- 162
- August 25, 2025
Investigation raises concerns over tooth stem cell banking claims

Parents are spending thousands of pounds to bank stem cells from their children’s milk teeth – but the recipient companies’ claims about their future medical value are unproven and potentially misleading, reveals an investigation by The BMJ, published today. The companies’ claims include that stem cells banked from teeth are already being used in treatments for autism and diabetes. They also highlight current research using stem cells in multiple sclerosis, Parkinson’s disease, and heart attacks. Tooth stem cell banking involves parents sending their children’s lost milk teeth to a laboratory where the dental pulp stem cells are harvested and stored. The service costs around £1900 (€2189; $2573) with an additional annual storage fee of £95, explains freelance journalist Emma Wilkinson. The three companies in the UK offering tooth stem cell banking – Future Health Biobank, BioEden and Stem Protect – all operate through one laboratory. Future Health Biobank says on ...
- Source: drugdu
- 167
- August 21, 2025
Seniors Neglecting Steps To Protect Heart Health, Study Says

By Dennis Thompson HealthDay ReporterWEDNESDAY, Aug. 20, 2025 (HealthDay News) — Seniors with known heart-related problems aren’t doing a very good job taking steps to protect their health, a new study says. Older folks with high blood pressure, stroke survivors and heart failure patients in the United States all have been neglecting Life’s Essential 8 — a checklist of lifestyle factors that can protect heart health, researchers found. “On average, participants with one cardiovascular disease had a Life’s Essential 8 score 9 points lower than those without cardiovascular disease,” lead researcher James Walker, a medical student at Northwestern University in Chicago, said in a news release. Life’s Essential 8 recommends that people eat healthy, exercise, avoid smoking, sleep better, lose excess weight, and manage their cholesterol, blood sugar and blood pressure levels, according to the American Heart Association. For this study, researchers analyzed a sample of more than 3,000 adults ...
- Source: drugdu
- 138
- August 21, 2025
Pfizer’s $5.4 billion gamble fails

Recently, Pfizer announced that its key sickle cell disease drug inclacumab failed to reach the primary endpoint in the phase III THRIVE-131 study. This news casts a shadow over Pfizer’s layout in this field. The Phase III THRIVE-131 study was designed to evaluate the effect of inclacumab in reducing vaso-occlusive crises. The results of the study showed that there was no significant difference in the incidence of vascular occlusive crisis between the inclacumab group and the placebo group, and inclacumab failed to achieve a statistically significant effect. Sickle cell disease (SCD) is a hereditary blood disorder in which red blood cells are sickle-shaped due to abnormalities in hemoglobin molecules, affecting blood flow and oxygen delivery. Patients often have symptoms such as pain and anemia, and may face many difficulties in life due to sudden illness, which brings a heavy burden to patients and families. Looking back at Pfizer’s layout of ...
- Source: drugdu
- 121
- August 21, 2025
InnoCare Pharma’s new anticancer drug Mesutoclax completes first patient dosing in clinical trial

InnoCare Pharma announced on August 21 that the first patient was dosed in the registrational clinical trial of the company’s independently developed novel BCL2 inhibitor Mesutoclax (ICP-248) for the treatment of mantle cell lymphoma (MCL) previously treated with BTK inhibitors. Mesutoclax is a novel, oral, highly selective BCL2 inhibitor. BCL2 is a key regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development and progression of various hematological malignancies. Mesutoclax selectively inhibits BCL2, restoring the programmed cell death mechanism in tumor cells, thereby exerting its anti-tumor efficacy. This unique mechanism of action holds great potential for the treatment of MCL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other indications. InnoCare Pharma is currently advancing clinical trials for these indications globally. This registrational clinical trial is designed to evaluate the safety and efficacy of mesutoclax in patients with MCL ...
- Source: drugdu
- 152
- August 21, 2025
Novartis’ innovative drug Noradrena approved for IgA nephropathy in China

On August 20, Novartis Group announced that its innovative product, Noradrena® (atrasentan hydrochloride tablets), has received approval from the National Medical Products Administration (NMPA) for the reduction of proteinuria in adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) at risk of rapid disease progression. Noradrena is reportedly the first non-immunological therapy approved in China for the treatment of IgA nephropathy and the first and currently only highly selective endothelin A (ETA) receptor antagonist for this indication. https://finance.eastmoney.com/a/202508203489375117.html
- Source: drugdu
- 196
- August 21, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.